Sandoz Neulasta Biosimilar Under FDA Review; Where's Apotex?
This article was originally published in Scrip
Executive Summary
Novartis AG unit Sandoz Inc. has its third biosimilar application under review at the FDA – this time seeking approval to market a version of Amgen Inc.'s Neulasta (pegfilgrastim), a leukocyte growth factor.